|
Active substance |
entrectinib |
|
Holder |
Roche |
|
Status |
Closed |
|
Indication |
adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with Central Nervous System (CNS) metastases, harbouring a ROS1 gene fusion, who have not received prior ROS1 inhibitor |
|
Public documents |
|
|
Last update |
08/08/2022 |
entrectinib
Last updated on 02/10/2024